Nonhormonal Hot-Flash Treatments That Have Evidence
A real treatment menu exists outside systemic hormones. The options work differently and deserve better than the phrase 'just try supplements.'
“I cannot take hormones” is sometimes followed by a pause long enough to suggest the consultation has run out of ideas. “I would rather not” can get the same treatment. Neither sentence means that the only remaining choices are a fan, a gummy and endurance.
The plain version: several nonhormonal treatments for hot flashes have real evidence. Certain prescription medicines, menopause-focused CBT and clinical hypnosis are recommended by The Menopause Society’s 2023 review. They do not all do the same thing: some reduce episode frequency, some reduce how disruptive symptoms feel, and each has practical tradeoffs. The best option is the one that fits your history and the problem you want to solve, not the one with the prettiest label.
What’s going on
Hot flashes and night sweats are vasomotor symptoms, meaning that changes in the brain’s temperature-regulation system trigger heat and sweating responses. Systemic estrogen can reduce them, but it is not the only way to influence the pathways or the burden of symptoms. Nonhormonal prescription treatments act through different mechanisms, while behavioral treatments can change symptoms, sleep or the degree of interference [1]. The category “nonhormonal” tells you what an approach does not contain; it does not tell you how effective, safe or accessible it is.
The first task is deciding what is being measured. An episode count matters if you are having frequent daytime flashes. Nighttime awakenings may be the real target if sleep is failing. A hot-flash problem rating asks how bothersome and disruptive the symptoms are. Someone can improve on that rating without the episode count falling by the same proportion. That is still a meaningful result, provided it is described honestly rather than translated into “the flashes stopped.”
Is it the change, or something else?
| Pattern | Menopausal possibility | Another contributor | Get assessed promptly if |
|---|---|---|---|
| Brief waves of heat | Typical vasomotor symptom | Medication effects, thyroid disease | New pattern with fever or unexplained illness |
| Night sweats with poor sleep | Menopausal episodes may wake you | Sleep apnea, infection, mood disorder | Drenching sweats with systemic symptoms |
| Palpitations during episodes | Sometimes accompany flashes | Arrhythmia, stimulants, anxiety | Chest pain, fainting or shortness of breath |
| Hot flashes during cancer treatment | Treatment can cause vasomotor symptoms | Other treatment effects | New symptom your oncology team asks you to report |
If cancer treatment is part of your history, involve the oncology team in treatment choices. “Nonhormonal” does not automatically mean every medicine or supplement is appropriate alongside cancer drugs. A pharmacist can review interactions. The same applies if you take several medicines or have liver, kidney or cardiovascular conditions.
What helps, and how well
Prescription options. The Menopause Society’s 2023 position statement recommends selected SSRIs and SNRIs, gabapentin and fezolinetant on Level I evidence; oxybutynin has Levels I to II support [1]. These are classes and medicines with different side effects, interactions and reasons to avoid them. An antidepressant used for hot flashes does not mean the symptom was “all in your head.” A medicine can have more than one clinical use. Ask what benefit the clinician expects for your symptom pattern and how it will be measured.
Fezolinetant targets a temperature-regulation pathway rather than supplying hormones. In the placebo-controlled SKYLIGHT 1 phase 3 trial, women with frequent moderate-to-severe symptoms had greater reductions in hot-flash frequency and severity than the placebo group [6]. That is stronger evidence than an open-label testimonial. It is also not a medicine to obtain without a safety discussion: the FDA has warned of rare but serious liver injury and calls for liver testing before and during treatment [7]. Ask about that monitoring and whether your health history changes suitability. The monitoring is part of treatment, not an optional footnote.
Menopause-focused CBT. This is a structured treatment, not an instruction to think positive while overheating. It addresses the thoughts, behaviors and sleep responses that can make symptoms more disruptive. NICE recommends considering it alongside hormone therapy, when hormone therapy is contraindicated, or when a person prefers not to use hormones [2]. In the MENOS4 trial among women with breast cancer, group CBT improved hot-flash and night-sweat problem ratings more than usual care at 26 weeks [3]. That is particularly relevant to how symptoms affect daily life; it should not be presented as proof that CBT erases every physical episode.
Clinical hypnosis. The large 2013 trial enrolled 187 postmenopausal women with frequent flashes and compared five clinician-led sessions with structured attention. Both diary outcomes and physiological monitoring favored hypnosis over the comparison [4]. A newer 250-person trial of a defined self-administered audio program also found a greater reduction in hot-flash scores than an active audio control at six weeks, though both groups improved [5]. These studies make hypnosis a credible option. They do not validate every recording or practitioner claim, and long-term outcomes still need study.
Systemic hormone therapy. It remains the most effective treatment for hot flashes, according to the same 2023 review [1]. A fair nonhormonal article says that aloud. If you avoid it because of a personal medical contraindication, the alternatives deserve a serious hearing. If you avoid it because of a headline from years ago, ask for a current, individualized discussion of benefits and risks before ruling it out. You may still choose a nonhormonal route. It should be your choice with useful information attached.
Local vaginal treatment. Vaginal moisturizers, lubricants and local hormonal treatment address vaginal dryness or discomfort, not the thermostat problem causing hot flashes. You may need a separate plan for those symptoms. One treatment’s success with flashes does not prove it will help painful sex or recurrent urinary symptoms. Tell the clinician both problems if you have both.
Comfort and products. A fan, lighter layers and a glass of cold water may make an episode easier to get through. Use what helps you. The 2023 evidence review did not recommend cooling techniques as a treatment for reducing vasomotor symptoms, nor did it recommend supplements and herbal remedies on the available evidence [1]. That is a statement about demonstrated treatment effects, not a ban on personal comfort. It is also a reason to be skeptical of a product promising “hormone balance” without defining the term or showing what is in the bottle.
How strong is the evidence? Several named medicines and structured behavioral treatments have randomized trials and guideline support. Their comparisons, outcomes and follow-up times differ, so there is no honest single ranking for every person. The evidence for herbal blends is much weaker than the marketing. Safety information matters as much as efficacy, particularly for prescription choices and possible interactions.
Choose the outcome before the option
Write down what a better month would look like. Fewer daytime interruptions? Sleeping through most nights? Less dread before a meeting? A treatment that improves one of those may be worthwhile even if it does not eliminate every flash. Conversely, a statistically significant average result may be too small to matter to you. Ask the clinician what magnitude of change is realistic and when to decide whether a trial has worked.
Access matters. A therapist-led program may be difficult to find or afford. A daily medicine requires remembering it and accepting possible side effects. An audio program is more accessible, but the evidence supports the studied protocol rather than an arbitrary app. These are not superficial details. A treatment that cannot be obtained or sustained is not a useful plan, however impressive its trial result.
Ask about the practical follow-through before starting. How soon should you expect a change, and who will help if an adverse effect appears? If the preferred treatment is unavailable, ask which alternative has evidence for the same outcome. A plan that includes access, monitoring and a review date is easier to use than a list of names handed over at the end of a visit.
If the first option fails, revisit the diagnosis and the goal. Was the main problem insomnia rather than episode count? Is another medicine causing heat or disrupted sleep? Did the side effects outweigh a modest improvement? A good follow-up changes the plan based on that information. It does not tell you that you failed at relaxing.
Notice that evidence for one symptom does not transfer automatically to another. A prescription that reduces hot flashes may not treat vaginal dryness. CBT that lowers hot-flash bother may not replace CBT-I for chronic insomnia or treatment for major depression. If you have several symptoms, ask which one each part of the plan addresses. A small, explicit combination of approaches can make more sense than expecting one “menopause treatment” to cover a list of unrelated outcomes. This is especially important when the first treatment helps partially: partial benefit is information, not proof that the entire approach was wrong.
Take this to your appointment
- “Systemic hormones are [not suitable for me / not my preference]. Which evidence-based nonhormonal choices fit my history?”
- “Is my main target fewer episodes, better sleep or less interference, and which treatment best matches that goal?”
- “What interactions or side effects matter with my current medicines?”
- “If we consider fezolinetant, what liver testing and follow-up are required?”
- “Can you refer me to a menopause-focused CBT or clinical-hypnosis program with a defined protocol?”
- “When will we decide whether this treatment helped enough to continue?”
See a clinician promptly if… you have any bleeding after 12 months without a period, very heavy or prolonged bleeding, new chest pain, a painful swollen leg or sudden shortness of breath, or low mood that won’t lift. If you are thinking about harming yourself, call or text 988 in the US, or call 911 in an emergency. This article is general education, not medical advice.
See hot flashes and night sweats for the full treatment picture and hormone therapy risks explained for the decision you may be weighing.
Frequently asked questions
Can hot flashes be treated without hormones?
Yes. Several prescription medicines and structured behavioral approaches have randomized-trial evidence. A clinician can help match the choice to your medical history and treatment goal.
Does CBT stop hot flashes?
Menopause-focused CBT can reduce how disruptive or distressing episodes feel and may improve coping with sleep problems. Trials often measure bother and interference, not just episode frequency.
Is fezolinetant a supplement?
No. It is a prescription nonhormonal medicine for moderate to severe vasomotor symptoms. FDA safety guidance warns about rare serious liver injury and calls for liver testing before and during treatment.
Which supplement works best?
The Menopause Society's 2023 evidence review did not recommend herbal remedies or supplements for hot flashes because benefits were not reliably demonstrated. Discuss any product you take because ingredients can interact with medicines.
Sources and further reading
- The Menopause Society: 2023 nonhormone therapy position statement
Evidence tiers for medicines, CBT, hypnosis and approaches not recommended for vasomotor symptoms.
- NICE NG23: Menopause identification and management
Updated recommendations on menopause-specific CBT and management discussions.
- MENOS4 randomized trial of group CBT for hot flashes in breast cancer survivors
Active comparison showing improvement in hot-flash and night-sweat problem ratings.
- Elkins et al.: Clinical hypnosis for postmenopausal hot flashes
187-person randomized trial with structured attention comparison and physiological monitoring.
- Elkins et al.: Self-administered hypnosis versus audio control
2025 randomized trial of 250 postmenopausal women; supports a defined audio protocol.
- SKYLIGHT 1 randomized trial of fezolinetant
Phase 3 placebo-controlled study in women with frequent moderate-to-severe vasomotor symptoms.
- FDA: Fezolinetant liver-injury safety communication
FDA warning on rare serious liver injury and need for liver monitoring.
Sources checked October 18, 2026. This is an editorial summary, not a systematic review or individual advice.